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Abstract
Background
Syntaxin-binding protein 1, encoded by STXBP1, is highly expressed in the
brain and involved in fusing synaptic vesicles with the plasma membrane. Stud-
ies have shown that pathogenic loss-of-function variants in this gene result in
various types of epilepsies, mostly beginning early in life. We were interested to
model pathogenic missense variants on the protein structure to investigate the
mechanism of pathogenicity and genotype–phenotype correlations.
Methods
We report 11 patients with pathogenic de novo mutations in STXBP1 identified
in the first 4293 trios of the Deciphering Developmental Disorder (DDD) study,
including six missense variants. We analyzed the structural locations of the
pathogenic missense variants from this study and the literature, as well as pop-
ulation missense variants extracted from Exome Aggregation Consortium
(ExAC).
Results
Pathogenic variants are significantly more likely to occur at highly conserved
locations than population variants, and be buried inside the protein domain.
Pathogenic mutations are also more likely to destabilize the domain structure
compared with population variants, increasing the proportion of (partially)
unfolded domains that are prone to aggregation or degradation. We were
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unable to detect any genotype–phenotype correlation, but unlike previously
reported cases, most of the DDD patients with STXBP1 pathogenic variants did
not present with very early-onset or severe epilepsy and encephalopathy, though
all have developmental delay with intellectual disability and most display behav-
ioral problems and suffered seizures in later childhood.
Conclusion
Variants across STXBP1 that cause loss of function can result in severe intellec-
tual disability with or without seizures, consistent with a haploinsufficiency
mechanism. Pathogenic missense mutations act through destabilization of the
protein domain, making it prone to aggregation or degradation. The presence
or absence of early seizures may reflect ascertainment bias in the literature as
well as the broad recruitment strategy of the DDD study.
Introduction
Brain function relies on the release of neurotransmitters
from chemical synapses, which in turn relies on the rapid
and regulated fusion of synaptic vesicles with the plasma
membrane. The central machinery involved in the fusion
process is composed of two conserved protein families:
the SNARE (soluble N-ethylmaleimide-sensitive factor
attachment receptor) and the SM (Sec1/Munc18) proteins
(S€udhof and Rothman 2009), now known as syntaxin-
binding proteins. Heterozygous pathogenic variants in
syntaxin-binding protein 1 (STXBP1, previously called
Munc18-1), encoded by the STXBP1 gene, have been
reported in nearly 200 patients with various types of
developmental disorders, primarily epilepsy/epileptic
encephalopathy, developmental delay, and intellectual dis-
ability (Saitsu et al. 2008, 2010; Otsuka et al. 2010; Milh
et al. 2011; Neale et al. 2012; Epi 4K Consortium and
Epilepsy Phenome/Genome Project 2013; Romaniello
et al. 2014, 2015; Weckhuysen et al. 2013; Barcia et al.
2014; Carvill et al. 2014; Michaud et al. 2014; Tso et al.
2014; Keogh et al. 2015; Khaikin and Mercimek-Mahmuto-
glu 2016; Stamberger et al. 2016). Although the mechanism
of disease is consistent with autosomal dominant haploin-
sufficiency, the mode by which pathogenic missense vari-
ants cause disease still remains unclear.
Many details about the molecular basis of membrane
fusion remain to be established (Rizo and Xu 2015), but
it is believed that STXBP1 plays an essential role in
synaptic vesicle docking, priming, and fusion (Toonen
and Verhage 2007; S€udhof and Rothman 2009; Carr and
Rizo 2010), and is highly expressed in the brain (Uhlen
et al. 2015). To mediate these different functions, STXBP1
is involved in multiple types of interaction with SNAREs,
of which the interaction with syntaxin-1 is the most
important. Syntaxin-1 can be folded in an open and
closed conformation. In the closed conformation, a short
sequence at the N-terminus (the N-peptide) and an
N-terminal three helix bundle (the Habc domain) are held
in a compact autoinhibitory conformation that hinders
interactions with other SNAREs to form the SNARE com-
plex. STXBP1 initially binds syntaxin-1 in the closed con-
formation, accounting for the regulating function of the
protein. Studies have suggested it is responsible for trans-
porting syntaxin-1 to the plasma membrane in the closed
conformation, where it facilitates vesicle fusion (Fig. 1)
(Arunachalam et al. 2008; Han et al. 2009; Ma et al.
2011; Martin et al. 2013).
The crystal structure of STXBP1 in complex with syn-
taxin-1 shows that it binds in the closed conformation to
the syntaxin-1 N-peptide and the Habc domain, PDB
accession 3c98 (Misura et al. 2000; Burkhardt et al. 2008).
STXBP1 adopts an arch-shaped structure consisting of
three domains: domain 1, domain 2, and domain 3,
where domain 3 is subdivided into domain 3a and 3b,
assigned by Misura et al. (2000) (Fig. 2). Domain 1 and
domain 3a form the cavity that binds the Habc domain
and the SNARE motif of syntaxin-1. Furthermore, the
opposite side of domain 1 binds to the N-peptide.
STXBP1 binds to the four helix bundle of the SNARE
complex (Dulubova et al. 2007; Shen et al. 2007) and
Figure 1. Cartoon representation of the role of STXBP1 in priming
vesicle fusion, showing binding to syntaxin-1 (closed conformation)
and other members of the SNARE complex.
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there is evidence that this binding is mediated by the
same cavity that binds syntaxin-1 (Shen et al. 2010; Xu
et al. 2010) as well as domain 3a (Hu et al. 2011; Pari-
sotto et al. 2014). Experiments with the STXBP1 homolog
in yeast (Sec1p) suggested that the binding takes place via
the groove between domains 1 and 2 (Hashizume et al.
2009; Weber-Boyvat et al. 2016). Every domain of
STXBP1 therefore plays a putative role in its function.
This study aims to further explain why pathogenic vari-
ants in STXBP1 lead to disease and hopefully thereby gain
a better understanding of the protein. Here we describe
11 new patients from the Deciphering Developmental
Disorder (DDD) study with pathogenic de novo muta-
tions in STXBP1 (Deciphering Developmental Disorders
Study 2017). We provide detailed clinical data and
analyze the structural consequences of the de novo mis-
sense mutations. We will also compare pathogenic
missense variants from the literature with the population
missense variants from the Exome Aggregation Consor-
tium (ExAC) (Lek et al. 2016), which is depleted of severe
pediatric conditions and therefore assumed not to have
individuals with severe intellectual disability (ID) or sig-
nificant developmental delay, to investigate the differences
between tolerated and nontolerated missense variants
from a protein structure perspective.
Materials and Methods
Ethical compliance
The DDD study has UK Research Ethics Committee
approval (10/H0305/83, granted by the Cambridge South
REC, and GEN/284/12 granted by the Republic of Ireland
REC). Postdiagnostic phenotyping was carried out within
the Phenotypes in Intellectual Disability study, with inde-
pendent Ethics Committee approval (11/EE/0330, granted
by Cambridge Central REC).
Clinical and genomic data
All patients were recruited as family trios into the DDD
study from Regional Genetic Services across the United
Kingdom because of an unexplained developmental disor-
der, including severe neurodevelopmental disorders, and/
or congenital anomalies, abnormal growth parameters,
dysmorphic features, and unusual behavioral phenotypes.
Genome-wide microarray and whole exome sequencing
were performed on all patients as detailed previously
(Deciphering Developmental Disorders Study 2015). De
novo mutations in STXBP1 (NM_003165.3; ENSG00
000136854) were identified in 11 of the 4293 probands
(0.26%) using trio exome sequencing, and deposited into
the DECIPHER database (Bragin et al. 2014). The results
were subsequently validated in diagnostic molecular
genetic laboratories by Sanger sequencing, and given to
the families via their clinical teams.
Clinical characteristics at the time of recruitment to the
DDD project were provided by referring clinical geneti-
cists via the DECIPHER website (Bragin et al. 2014) using
HPO terminology (Koehler et al. 2014). Diagnosed
patients were subsequently invited to participate in
detailed research phenotyping, and 10 patients partici-
pated. The assessment protocol included a structured
medical history interview, neurological examination,
assessment of global and specific functional abilities
(Vineland Adaptive Behavior Scales), and standardized
behavior questionnaire appropriate for young people with
ID (Developmental Behavior Checklist) (Einfeld and
Tonge 2002).
Structural analysis
The structural analysis was performed on PDB accession
3c98 (Misura et al. 2000; Burkhardt et al. 2008), which
contains the rat structure of STXBP1 (100% sequence
identity to the human protein) in complex with the
N-terminal part of syntaxin-1. The structures were ana-
lyzed and figures made using CCP4mg (McNicholas et al.
2011). The structural analysis of STXBP2 (64% sequence
identity to STXBP1) was performed on PDB accession
4cca. The structures were superposed using the superpose
function from the CCP4 suite to compare residue coordi-
nates. The superpose function is based on secondary struc-
ture and iterative three-dimensional alignment of protein
backbone C-alpha atoms (Krissinel and Henrick 2004).
Residue conservation was retrieved from ConSurf (Dodge
Figure 2. Domain architecture of syntaxin-binding protein 1. The
distribution of the population missense variants from ExAC are shown
as a density plot on top (black) and is based on 65 unique missense
variants; the bottom distribution shows all pathogenic variants from
this study and the literature (magenta), and is based on 40 unique
missense variants.
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et al. 1998; Ashkenazy et al. 2010), and used 150
sequences predicted to be structurally similar to PDB
accession 3c98. Residue accessibility, a measure of how
buried individual amino acids are within the domain
structure, was calculated using Naccess (Hubbard and
Thornton 1993). The change in thermodynamic stability
upon mutation and the number of amino acid interac-
tions were calculated using FoldX PositionScan and
PrintNetworks commands (Schymkowitz et al. 2005).
Population missense variants, 71 in total, were retrieved
from the ExAC, MA (http://exac.broadinstitute.org). Read
data were manually checked for all variants to exclude
mosaic variants. The ExAC lists pathogenic variants in the
second isoform of STXBP1 (Uniprot identifier: P61764-2
instead of P61764-1), where the last 18 amino acids are
replaced by 27 different ones. Since the structure is based
on the first isoform, the six variants in the last part of the
protein were discarded. This leaves 65 population variants
to be used for analysis.
Results
Patient data
Table 1 lists detailed phenotypes of all 11 patients with de
novo STXBP1 mutations identified by the DDD study,
with DECIPHER IDs (Bragin et al. 2014). Seven patients
were female and four were male; their age range was 1.6–
15.5 years. Only two were born prematurely (<37 weeks
completed gestational age). None of the patients had
intrauterine growth retardation and only one patient had
microcephaly (head circumference <2nd centile).
Although six patients had some facial dysmorphism, there
were no consistent dysmorphic findings in this group.
Other low-frequency findings in these patients included
gastroesophageal reflux, tapered fingers, eye problems,
and joint laxity.
All patients had developmental delay, with age range
for starting to walk independently from 2.1 to 8 years. All
patients had ID with speech and language delay, and four
patients have not yet developed speech. Only one patient
developed speech at an appropriate age, though it is still
very limited. Six patients were assessed using the Vineland
Adaptive Behavior Scales (parental interview) and all had
low scores with four in the severe ID range (26, 33, 30,
and 31) and two in the moderate ID range (47 and 45).
On average, communication skills and daily living skills
were as expected for global ability, whereas motor skills
and social abilities were slightly stronger than expected.
Eight patients had behavioral problems, three having
some form of anxiety and three having stereotypies or
repetitive behaviors such as hand flapping. Two patients
had been diagnosed with an autism spectrum disorder
and three patients showed some aggressive behaviors.
Where available and with one exception, standardized
questionnaire ratings indicated much higher risk of
behavior problems than expected for age or ID severity,
with highest scores in the self-absorbed, disruptive, and
communication disturbance domains.
Eight patients had a history of epilepsy. Seizure types,
severity, and age of onset varied widely within the group.
One patient had severe infantile encephalopathy, one
patient had absence seizures with a single generalized
tonic–clonic seizure, one patient had absence seizures
with several generalized seizures, three patients had com-
plex partial seizures, and two patients had seizures with
no further details available. An additional patient also had
unilateral twitching and clenched hands during infancy
only, though it is unclear if these were seizures. The
remaining two patients had not had any seizures at the
last clinical assessment. Only one of the patients had early
infantile epileptic encephalopathy. Nine patients had
abnormal neurological findings, particularly tremor,
which was seen in six patients. Hypotonia and ataxia were
each seen in three patients. Ten patients had neuroimag-
ing (MRI brain in nine and CT brain in one), but only
one MRI brain scan was reported to be abnormal (bilat-
eral symmetrical abnormalities in anterior temporal lobe).
Variant data and comparative protein
modeling
The 11 de novo STXBP1 mutations identified in DDD
include three frameshift, two nonsense, and six missense
changes (Table 1; note that the same missense pathogenic
variant was present in two unrelated patients). Table 2
lists the results of standard in silico analyses of the
pathogenicity of the five missense variants identified in
our patients. Four of these variants have been reported
previously, all in patients with early-onset epileptic
encephalopathy. The c.533C>T; p.(Thr178Ile) variant has
not been reported previously.
The literature contains over 50 reported missense vari-
ants in STXBP1 resulting in developmental disorders
(summarized in Stamberger et al. 2016), and there are a
further 65 population missense variants retrieved from
the ExAC database (Lek et al. 2016), which are presumed
to be benign with respect to severe childhood disorders.
The location of unique missense variants in these two
datasets – disease-causing and population – is shown in
the two-dimensional (2D) protein domain structure in
Figure 2 and the three-dimensional (3D) protein struc-
ture in Figure 3. Both types of missense variants are scat-
tered throughout the different structural domains of the
protein, with no significant enrichment of disease-causing
variants in any specific area of the protein, reflecting the
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fact that STXBP1 is a highly constrained gene, with fewer
loss-of-function variants (pLI = 1) and missense variants
(z = 5.22) than expected throughout the gene (Lek et al.
2016).
Amino acids that are altered in the population versus
those that cause disease nonetheless differ significantly in
terms of their residue accessibility (RSA) (Fig. 4A), their
sequence conservation (Fig. 4B), the number of interact-
ing amino acids within the STXBP1 domain (Fig. 4C),
though not with syntaxin-1 (Fig. 4D), and their predicted
change in structural stability upon mutation (Fig. 4E).
The RSA of the disease-associated pathogenic variants is
significantly lower than that of the population variants
and of all residues in the protein (Wilcoxon–Mann–Whit-
ney test, P = 6e-8 and P = 2e-5, respectively), while the
population variants are also significantly different from all
residues in the protein (P = 2e-5). This indicates that the
pathogenic changes are significantly more often located in
the core of the protein, while the population variants are
more likely to occur on the surface, as has been noted in
the 1000 genomes project (de Beer et al. 2013). Addition-
ally, the residue conservation of the disease-causing vari-
ants is significantly higher than that of the population
variants and of all residues in the protein (P = 1e-9 and
P = 8e-7, respectively), while the conservation of the
population variants is significantly lower than all residues
in the protein (P = 3e-6). The amino acids where patho-
genic variants occur have significantly more interactions
with other amino acids in STXBP1 than those where pop-
ulation variants occur (P = 5e-5), though there is no dif-
ference in interactions with syntaxin-1. Pathogenic
variants are predicted to be significantly more destabi-
lized, relative to the wild type, than population variants
(P = 7e-10).
Interestingly, variants of Val84 and His445 occur in
both the patient and population datasets, though different
amino acids are substituted between the datasets: Val84Ile
and His445Tyr (number of alleles present in ExAC was
54 and 1, respectively; Grantham distances of 29 and 83,
respectively) occurred in developmentally normal individ-
uals, whereas Val84Asp and His445Pro (Grantham dis-
tances of 121 and 77, respectively) were found to cause
developmental problems in children. At position 84, iso-
leucine (the population variant) is present in 30% of the
150 aligned sequences used for conservation analysis
(Ashkenazy et al. 2010), while aspartic acid (the patho-
genic variant) is not present in any of the aligned
sequences; in addition, isoleucine shares many amino acid
properties with valine, while aspartic acid is very different
being both larger and negatively charged. At position 445,
Table 2. Analysis of the five missense variants identified in STXBP1 in the DDD Study.
DECIPHER ID 258815 261841 265950 and 270001 273873 272650
STXBP1 mutation c.704G>A;
p.Arg235Gln
c.1631G>T; p.Gly544Val c.568C>T; p.Arg190Trp c.1651C>T;
p.Arg551Cys
c.533C>T;
p.Thr178Ile
PhyloP 5.69 5.61 2.38 5.61 5.61
Grantham distance 43 109 101 180 89
Align GVGD C35 C0 C65 C0 C15
SIFT 0 0 0 0 0
PROVEAN Damaging Damaging Damaging Damaging Damaging
Polyphen 2 0.994 1 0.999 0.897 0.535
Mutation taster Disease causing Disease causing Disease causing Disease causing Disease
causing
SNPs&GO Disease related Disease related Disease related Disease related Neutral
ClinVar
dbSNP c.704G>A;
p.Arg235Gln
(rs794727970)
Not present c.568C>T; p.Arg190Trp
(rs796053355 - pathogenic)
Not present Not present
ExAC Not present Not present Not present Not present Not present
Protein domain 2 2 2 2 2
Literature (Phenotype) Stamberger et al.
(2016) (EOEE)
Weckhuysen et al.
(2013) (EOEE?West)
Carvill et al. (2014)(EOEE);
Epi 4k Consortium
2014 (EOEE??LSG)
Neale et al. (2012)
(autism study);
Weckhuysen
et al. (2013) (EOEE);
Stamberger et al. (2016)
(2 patients both with EOEE)
Not
previously
reported
PhyloP (Pollard et al. 2010), Grantham distance (Grantham 1974), Align GVGD (Tavtigian et al. 2006), SIFT (Kumar et al. 2009), PROVEAN (Choi
et al. 2012), Polyphen-2 (Adzhubei et al. 2010), Mutation Taster (Schwarz et al. 2010), SNPs&Go (Calabrese et al. 2009), dbSNP (Sherry et al.
2001), ExAC (Lek et al. 2016). EOEE, early-onset epileptic encephalopathy; LGS, Lennox–Gastaut syndrome.
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histidine is only present in 28% of aligned sequences and,
although the location tolerates a wide variety of amino
acids, tyrosine (the population variant) is present in 14%
of alignments, while proline (the pathogenic variant) is
never present. Moreover, since the residue is located in a
helix, the restricted backbone φ and w angles necessitated
by a proline residue would likely break or substantially
destabilize the helix. In both cases (positions 84 and 445),
the pathogenic variant is predicted to cause a substantial
decrease in protein stability relative to the wild type,
while the population variant is predicted to be slightly
stabilizing. These examples demonstrate the value of pro-
tein structural analysis in predicting whether a specific
pathogenic variant will be deleterious or not.
The structural context of the five missense changes
identified by the DDD study is shown in Figure 5, and
their effect on the protein structure is considered in detail
below. All the DDD variants are in domain 2 of the
protein structure. Table 2 lists evidence for their
pathogenicity.
• Thr178 (mutated to Ile) is positioned in the center of
an a-helix, where its side chain hydroxyl forms an
hydrogen bond with the backbone oxygen of Gln175.
This bond would be lost upon substitution to isoleu-
cine, but it is uncertain if this causes the variant to be
deleterious. Perhaps the slightly larger size of isoleucine
destabilizes the protein fold. Thr178 is highly struc-
turally conserved (99%) and the only other amino acid
observed at this position is the even smaller amino acid
alanine.
• Arg190 (mutated, in two unrelated DDD children, to
Trp) is buried and forms three hydrogen bonds, two
with the backbone oxygen of Tyr499 and one with the
backbone oxygen of Leu494. This residue is 100% con-
served in the alignment. Replacement by tryptophan
will not only result in the loss of these hydrogen bonds,
it will also disrupt the protein fold. Tryptophan is less
flexible (two side chain torsion angles compared to four
in arginine) and substantially larger, causing steric
clashes with other residues in the core of the structure.
• Arg235 (mutated to Gln) is located in a loop and par-
takes in a network of electrostatic interactions. One of
Figure 3. Ribbon diagram of syntaxin-binding protein 1 (transparent,
colored by domain as in Figure 1) in complex with part of syntaxin-1
(red) with the Ca positions of pathogenic missense variants (magenta)
and population missense variants (gray). The N-peptide is shown in
the cylinder representation (bottom left).
Figure 4. Boxplots of (A) residue accessiblity (Hubbard and Thornton 1993), (B) sequence conservation (Dodge et al. 1998; Ashkenazy et al.
2010), (C) number of interacting amino acids within the STXBP1 domain or (D) with syntaxin-1, and (E) predicted change in stability of the
protein domain (Schymkowitz et al. 2005) for pathogenic (pink) and population (gray) missense variants.
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those interactions is a hydrogen bond between its own
backbone oxygen and Ne. This is the only interaction
that would remain upon changing arginine to glu-
tamine; all others would be lost. Furthermore, arginine
is the only residue that is able to occupy this very
specific space, hence its 100% residue conservation.
• Gly544 (mutated to Val) resides in a loop and is pre-
ceded by Gly543. Both the residues are 100% struc-
turally conserved and have φ and w angles (103° and
23° for Gly543 and 99° and 150° for Gly544) that other
residues are unable to have. These torsion angles allow
the loop to perfectly bridge the preceding b-strand with
the following a-helix in this limited space. Moreover,
substitution of Gly544 to valine would also result in a
steric interference with the overlying loop. Substitution
of this residue to aspartic acid and serine (Gly441Ser in
STXBP2) has already been found to be deleterious for
the protein (Cetica et al. 2010) indicating that any
pathogenic variant of Gly544 is likely to result in loss
of function.
• Arg551 (mutated to Cys) is sandwiched between two
negatively charged residues, forming a salt bridge with
one and a hydrogen bond with the other. Replacement
to cysteine would result in a loss of these interactions
and thereby compromise the stability of the protein.
Arg551 is 99% conserved, indicating the importance of
this residue at this position.
Discussion
It is well established that heterozygous loss-of-function
variants in STXBP1 – including whole gene deletion,
intragenic deletion, stop gain, frameshift, and splice
donor/acceptor variants – result in a severe childhood
developmental phenotype associated with seizures and ID.
The gene is highly evolutionarily constrained, with just
four apparent loss-of-function variants in the ExAC data-
base of population variation (Lek et al. 2016). These four
variants (three frameshift and one splice donor variant)
are all located at very C-terminal end of the protein, after
the end of the structured domain, and absent from the
first isoform, where they are unlikely to cause loss of
function.
In order to try and elucidate the mechanism of
pathogenicity of missense variants in STXBP1, we com-
pared population missense variants (from ExAC) with
pathogenic missense changes (from DDD and the litera-
ture). Although in principle the existence of a single pop-
ulation variant does not rule out pathogenicity, it is
unlikely that the observed population variants in STXBP1
are pathogenic, since severe early-onset childhood disor-
ders have specifically been excluded from ExAC. We eval-
uated missense changes in the 3D domain structure, but
were unable to find any positional correlation with
pathogenicity. Nonetheless, pathogenic missense variants
are significantly more likely to be buried within the
domain, at highly conserved residues that are involved in
a network of intramolecular interactions within STXBP1
(Fig. 4). There is no evidence that pathogenic variants
directly affect the binding interaction with syntaxin-1. We
also assessed the effect of both pathogenic and population
variants on the predicted thermodynamic stability of the
protein domain, relative to the wild type (Schymkowitz
et al. 2005), and found that the pathogenic changes were
significantly more likely to destabilize the domain
(Fig. 4). This provides good evidence that the mechanism
of pathogenicity for missense variants in STXBP1 is hap-
loinsufficiency, through destabilization of the native
folded state of the protein domain, making it prone to
misfolding, aggregation, and degradation (Nielsen et al.
2017). This mechanism has previously been suggested by
Saitsu et al. (2012), where direct evidence for destabiliza-
tion and aggregation was observed for several pathogenic
missense variants in STXBP1.
Heterozygous pathogenic variants in the STXBP1 gene
can be associated with ID phenotypes, with or without
epilepsy. The ID–epilepsy phenotypes include early
Figure 5. Structure of syntaxin-binding protein 1 with the positions
of the five missense pathogenic variants from the DDD study and
their structural surroundings shown as insets.
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infantile epileptic encephalopathy (EIEE) or Ohtahara syn-
drome (Saitsu et al. 2008), West syndrome (Deprez et al.
2010; Otsuka et al. 2010), Dravet syndrome (Carvill
et al. 2014), infantile spasms (Mignot et al. 2011; Carvill
et al. 2014; Michaud et al. 2014; Boutry-Kryza et al. 2015),
neonatal-onset or early-onset focal epilepsy (Vatta et al.
2012; Romaniello et al. 2014), partial complex epilepsy
(Hamdan et al. 2011), and nonsyndromic epilepsy (Ham-
dan et al. 2009; Deprez et al. 2010). These phenotypes are
invariably associated with ID and often with ataxia, tre-
mor, and sometimes with a movement disorder (Kanazawa
et al. 2010). Respiratory complex I and IV deficiency and
lactic acidemia without respiratory complex deficiency
have also been reported in single patients with STXBP1-
related epilepsy phenotypes (Barcia et al. 2014; Keogh
et al. 2015; Li et al. 2016), as has atypical Rett syndrome
(Olson et al. 2015; Romaniello et al. 2015).
However, intellectual disability phenotypes without sei-
zures have only been reported previously in a small num-
ber of patients with heterozygous STXBP1 pathogenic
variants (Hamdan et al. 2011; Campbell et al. 2012;
Rauch et al. 2012; Gburek-Augustat et al. 2016; Stam-
berger et al. 2016). These patients usually have severe ID,
often in combination with ataxia and tremor, with addi-
tional findings of autism, attention-deficit disorder, and
movement disorder in one or more patients. Stamberger
et al. recently reviewed the phenotypic spectrum of 147
patients with STXBP1 encephalopathy, including 45 previ-
ously unreported patients. A majority of these patients
presented with early-onset epilepsy and encephalopathy
(EOEE) or Ohtahara syndrome. Only 4 of the 45 (<10%)
previously unreported patients with STXBP1 pathogenic
variants had ID without seizures. Table S1 summarizes
the clinical findings and STXBP1 pathogenic variants in
12 previously reported patients with STXBP1 pathogenic
variants and ID without any seizures, as well as the two
patients from our cohort.
Only 1 of the 11 probands reported here presented
with an infantile epileptic encephalopathy phenotype,
though another seven had some form of seizures and all
had severe ID. Nonetheless, there is a clear underrepre-
sentation of severe, early-onset epilepsy phenotypes in our
patient cohort relative to those previously published with
mutations in STXBP1. This is unlikely to be related to the
type of pathogenic variant or its location, as patients in
our cohort had a range of stop gain, frameshift, and mis-
sense pathogenic variants spread across the protein. In
addition, four of the five missense pathogenic variants
that were identified in our cohort have been previously
reported to cause early-onset epileptic encephalopathy
(Table 2). This may reflect variability of the phenotype
associated with STXBP1 pathogenic variants, or the modi-
fying effects of variants in other genes. Interestingly,
STXBP1 knockout mice display a complete loss of neuro-
transmitter secretion from synaptic vesicles throughout
development leading to neurodegeneration, though sei-
zures have never been described (Verhage et al. 2000).
Another possible explanation for the lack of a severe
early-onset epilepsy phenotype in our cohort could be
ascertainment bias in the literature, which is absent from
the DDD Study due to its wide eligibility criteria (Wright
et al. 2015). We were unable to detect any genotype–phe-
notype correlation to explain the different presentation of
these cases, and therefore suggest that STXBP1 variants
resulting in loss of function can cause a broad develop-
mental phenotype associated with severe ID with or with-
out a variety of other behavioral and neurological
problems, particularly seizures/epilepsy, ataxia, and
tremor.
In conclusion, analysis of de novo pathogenic variants
in STXBP1 in a cohort of children with developmental
disorders confirms that loss-of-function variants in this
gene cause severe developmental delay with or without
seizures. Pathogenic variants in all domains of the pro-
tein encoded by STXBP1 can result in the phenotype of
ID with or without seizures, indicating that this pheno-
type does not correlate with the type or location of the
pathogenic variant, but is consistent with a haploinsuffi-
ciency mechanism. Structural analysis of the STXBP1
confirms that the pathogenic missense variants are
mostly buried inside the protein domain at highly con-
served residues where a variant is likely to destabilize the
domain and potentially lead to protein aggregation or
degradation.
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